FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116771018> ?p ?o ?g. }

• W2116771018 abstract "Placebo-controlled, randomized, phase 2b trial was conducted in 34 adults comprising 18 first-diagnosed (52.9%), 6 relapsed (17.6%), and 10 MDR-TB (29.4%) cases to investigate the safety and efficacy of an oral immune adjunct (V5). The immunotherapy (N = 24) and placebo (N = 10) arms received once-daily tablet of V5 or placebo for one month in addition to conventional anti-TB therapy (ATT) administered under directly observed therapy (DOT).The enlarged liver, total bilirubin, erythrocyte sedimentation rate, lymphocyte and leukocyte counts improved significantly in V5 recipients (P = 0.002; 0.03; 8.3E-007; 2.8E-005; and 0.002) but remained statistically unchanged in the placebo group (P = 0.68; 0.96; 0.61; 0.91; and 0.43 respectively). The changes in hemoglobin and ALT levels in both treatment arms were not significant. The body weight increased in all V5-treated patients by an average 3.5 ± 1.8 kg (P = 2.3E-009), while 6 out of 10 patients on placebo gained mean 0.9 ± 0.9 kg (P = 0.01). Mycobacterial clearance in sputum smears was observed in 78.3% and 0% of patients on V5 and placebo (P = 0.009). The conversion rate in V5-receiving subjects with MDR-TB (87.5%) seemed to be higher than in first-diagnosed TB (61.5%) but the difference was not significant (P = 0.62). Scoring of sputum bacillary load (range 3-0) at baseline and post-treatment revealed score reduction in 23 out of 24 (95.8%) V5 recipients (from mean/median 2.2/3 to 0.3/0; P = 6E-010) but only in 1 out of 10 (10%) patients on placebo (1.9/1.5 vs. 1.8/1; P = 0.34). No adverse effects or TB reactivation were seen at any time during follow-up. V5 is safe as an immune adjunct to chemotherapeutic management of TB and can shorten substantially the duration of treatment." @default.
• W2116771018 created "2016-06-24" @default.
• W2116771018 creator A5007075525 @default.
• W2116771018 creator A5014642799 @default.
• W2116771018 creator A5017520833 @default.
• W2116771018 creator A5020647289 @default.
• W2116771018 creator A5056769607 @default.
• W2116771018 creator A5066341153 @default.
• W2116771018 creator A5066416124 @default.
• W2116771018 creator A5075319242 @default.
• W2116771018 creator A5083250155 @default.
• W2116771018 date "2011-01-18" @default.
• W2116771018 modified "2023-10-10" @default.
• W2116771018 title "Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB" @default.
• W2116771018 cites W1500513666 @default.
• W2116771018 cites W1536595294 @default.
• W2116771018 cites W1593496730 @default.
• W2116771018 cites W2012110627 @default.
• W2116771018 cites W2013841287 @default.
• W2116771018 cites W2025328459 @default.
• W2116771018 cites W2033427201 @default.
• W2116771018 cites W2041108298 @default.
• W2116771018 cites W2043931621 @default.
• W2116771018 cites W2050760514 @default.
• W2116771018 cites W2052743310 @default.
• W2116771018 cites W2054524607 @default.
• W2116771018 cites W2071478811 @default.
• W2116771018 cites W2074850685 @default.
• W2116771018 cites W2100425421 @default.
• W2116771018 cites W2104727514 @default.
• W2116771018 cites W2118868279 @default.
• W2116771018 cites W2118877744 @default.
• W2116771018 cites W2126915439 @default.
• W2116771018 cites W2145740271 @default.
• W2116771018 cites W2161301537 @default.
• W2116771018 cites W2166822423 @default.
• W2116771018 cites W2263023695 @default.
• W2116771018 cites W2314604846 @default.
• W2116771018 doi "https://doi.org/10.1186/1476-8518-9-3" @default.
• W2116771018 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3031205" @default.
• W2116771018 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21244690" @default.
• W2116771018 hasPublicationYear "2011" @default.
• W2116771018 type Work @default.
• W2116771018 sameAs 2116771018 @default.
• W2116771018 citedByCount "17" @default.
• W2116771018 countsByYear W21167710182012 @default.
• W2116771018 countsByYear W21167710182013 @default.
• W2116771018 countsByYear W21167710182015 @default.
• W2116771018 countsByYear W21167710182016 @default.
• W2116771018 countsByYear W21167710182018 @default.
• W2116771018 countsByYear W21167710182020 @default.
• W2116771018 countsByYear W21167710182021 @default.
• W2116771018 countsByYear W21167710182022 @default.
• W2116771018 countsByYear W21167710182023 @default.
• W2116771018 crossrefType "journal-article" @default.
• W2116771018 hasAuthorship W2116771018A5007075525 @default.
• W2116771018 hasAuthorship W2116771018A5014642799 @default.
• W2116771018 hasAuthorship W2116771018A5017520833 @default.
• W2116771018 hasAuthorship W2116771018A5020647289 @default.
• W2116771018 hasAuthorship W2116771018A5056769607 @default.
• W2116771018 hasAuthorship W2116771018A5066341153 @default.
• W2116771018 hasAuthorship W2116771018A5066416124 @default.
• W2116771018 hasAuthorship W2116771018A5075319242 @default.
• W2116771018 hasAuthorship W2116771018A5083250155 @default.
• W2116771018 hasBestOaLocation W21167710181 @default.
• W2116771018 hasConcept C121608353 @default.
• W2116771018 hasConcept C126322002 @default.
• W2116771018 hasConcept C141071460 @default.
• W2116771018 hasConcept C142724271 @default.
• W2116771018 hasConcept C204787440 @default.
• W2116771018 hasConcept C27081682 @default.
• W2116771018 hasConcept C2776301714 @default.
• W2116771018 hasConcept C2777701055 @default.
• W2116771018 hasConcept C2778143017 @default.
• W2116771018 hasConcept C2781069245 @default.
• W2116771018 hasConcept C71924100 @default.
• W2116771018 hasConcept C90924648 @default.
• W2116771018 hasConceptScore W2116771018C121608353 @default.
• W2116771018 hasConceptScore W2116771018C126322002 @default.
• W2116771018 hasConceptScore W2116771018C141071460 @default.
• W2116771018 hasConceptScore W2116771018C142724271 @default.
• W2116771018 hasConceptScore W2116771018C204787440 @default.
• W2116771018 hasConceptScore W2116771018C27081682 @default.
• W2116771018 hasConceptScore W2116771018C2776301714 @default.
• W2116771018 hasConceptScore W2116771018C2777701055 @default.
• W2116771018 hasConceptScore W2116771018C2778143017 @default.
• W2116771018 hasConceptScore W2116771018C2781069245 @default.
• W2116771018 hasConceptScore W2116771018C71924100 @default.
• W2116771018 hasConceptScore W2116771018C90924648 @default.
• W2116771018 hasIssue "1" @default.
• W2116771018 hasLocation W21167710181 @default.
• W2116771018 hasLocation W21167710182 @default.
• W2116771018 hasLocation W21167710183 @default.
• W2116771018 hasLocation W21167710184 @default.
• W2116771018 hasOpenAccess W2116771018 @default.
• W2116771018 hasPrimaryLocation W21167710181 @default.
• W2116771018 hasRelatedWork W1527009504 @default.
• W2116771018 hasRelatedWork W2002120878 @default.
• W2116771018 hasRelatedWork W2003938723 @default.
• W2116771018 hasRelatedWork W2047967234 @default.

• next